Oncolytics Biotech Files 6-K Report
Ticker: ONCY · Form: 6-K · Filed: Jan 22, 2025 · CIK: 1129928
Sentiment: neutral
Topics: foreign-private-issuer, sec-filing, routine-disclosure
Related Tickers: ONCY
TL;DR
Oncolytics Biotech (ONCY) filed a standard 6-K, confirming Canadian base and 20-F reporting.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on January 22, 2025, reporting as a foreign private issuer for the month of January 2025. The company is based in Calgary, Alberta, Canada, and operates in the Pharmaceutical Preparations sector. This filing indicates they will file annual reports under Form 20-F.
Why It Matters
This filing provides routine disclosure for foreign private issuers, informing investors about the company's reporting status and location.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically increase risk.
Key Numbers
- 001-38512 — SEC File Number (Identifies the company's filing history with the SEC)
Key Players & Entities
- Oncolytics Biotech Inc. (company) — Filer of the report
- 20250122 (date) — Filing date
- January 2025 (date) — Reporting period
- Calgary, Alberta, Canada (location) — Company headquarters
- 001-38512 (other) — SEC file number
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer filed for the month of January 2025, providing routine disclosures to the SEC.
Where is Oncolytics Biotech Inc. located?
Oncolytics Biotech Inc. is located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
Under which form will Oncolytics Biotech Inc. file its annual reports?
Oncolytics Biotech Inc. will file its annual reports under cover of Form 20-F.
What is the SIC code for Oncolytics Biotech Inc.?
The Standard Industrial Classification (SIC) code for Oncolytics Biotech Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the filing date and reporting period for this 6-K?
The filing date is January 22, 2025, and the report covers the month of January 2025.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2025-01-22 07:00:46
Filing Documents
- form6kascogi2025abstracts.htm (6-K) — 18KB
- ascogiabstracts.htm (EX-99.1) — 34KB
- 0001129928-25-000004.txt ( ) — 53KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date January 22, 2025 Kirk Look Chief Financial Officer